{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:10:01Z","timestamp":1790205001516,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01595-5","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:01:38Z","timestamp":1728619298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia"],"prefix":"10.1186","volume":"16","author":[{"given":"Lisa","family":"Le Scouarnec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bouteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J","family":"van der Veere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M W","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Planche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Dufouil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"1595_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the Road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"1595_CR2","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid Pathology in persons without Dementia: a Meta-analysis. JAMA. 2015;313:1924\u201338.","journal-title":"JAMA"},{"key":"1595_CR3","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"J Bateman Randall","year":"2023","unstructured":"Bateman Randall J, Janice S, Paul DMCD, Rachid A, Stephen S, et al. Two phase 3 trials of Gantenerumab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;389:1862\u201376.","journal-title":"N Engl J Med"},{"key":"1595_CR4","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"1595_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1595_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512.","journal-title":"JAMA"},{"key":"1595_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease. N Engl J Med. 2023;389:1096\u2013107.","journal-title":"N Engl J Med"},{"key":"1595_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","volume":"178","author":"N Villain","year":"2022","unstructured":"Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer\u2019s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol. 2022;178:1011\u201330.","journal-title":"Rev Neurol"},{"key":"1595_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and \u03b2-Amyloid\u2013targeting antibodies: a systematic review. JAMA Neurol. 2022;79:291.","journal-title":"JAMA Neurol"},{"key":"1595_CR10","doi-asserted-by":"publisher","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S et al. Lecanemab: Appropriate Use Recommendations. J Prev Alz Dis. 2023; https:\/\/link.springer.com\/article\/. https:\/\/doi.org\/10.14283\/jpad.2023.30. Cited 2024 Feb 26.","DOI":"10.14283\/jpad.2023.30"},{"key":"1595_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-017-0288-0","volume":"9","author":"C Dufouil","year":"2017","unstructured":"Dufouil C, Dubois B, Vellas B, Pasquier F, Blanc F, Hugon J, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017;9:67.","journal-title":"Alzheimers Res Ther"},{"key":"1595_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1474-4422(18)30029-2","volume":"17","author":"B Dubois","year":"2018","unstructured":"Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, et al. Cognitive and neuroimaging features and brain \u03b2-amyloidosis in individuals at risk of Alzheimer\u2019s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018;17:335\u201346.","journal-title":"Lancet Neurol"},{"key":"1595_CR13","unstructured":"University, Hospital. Bordeaux. Longitudinal Study of Brain Amyloid imaGing in MEMENTO. clinicaltrials.gov; 2022 Feb. Report No.: NCT02164643. https:\/\/clinicaltrials.gov\/study\/NCT02164643"},{"key":"1595_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12149-017-1221-0","volume":"32","author":"M-O Habert","year":"2018","unstructured":"Habert M-O, Bertin H, Labit M, Diallo M, Marie S, Martineau K, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Ann Nucl Med. 2018;32:75\u201386.","journal-title":"Ann Nucl Med"},{"key":"1595_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","volume":"1","author":"N Mattsson","year":"2014","unstructured":"Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2014;1:534\u201343.","journal-title":"Ann Clin Transl Neurol"},{"key":"1595_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, For the Alzheimer\u2019s Disease Neuroimaging Initiative. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240\u20139.","journal-title":"Neurology"},{"key":"1595_CR17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.38.6.900","volume":"38","author":"E Grober","year":"1988","unstructured":"Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900\u2013900.","journal-title":"Neurology"},{"key":"1595_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2307\/1422696","volume":"100","author":"LL Thurstone","year":"1987","unstructured":"Thurstone LL. Psychophysical analysis. By L. L. Thurstone, 1927. Am J Psychol. 1987;100:587\u2013609.","journal-title":"Am J Psychol"},{"key":"1595_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","volume":"19","author":"T Tombaugh","year":"2004","unstructured":"Tombaugh T. Trail making test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203\u201314.","journal-title":"Arch Clin Neuropsychol"},{"key":"1595_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242:557\u201360.","journal-title":"J Neurol"},{"key":"1595_CR21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822\u201338.","journal-title":"Lancet Neurol"},{"key":"1595_CR22","doi-asserted-by":"crossref","unstructured":"Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. Perry G, Avila J, Tabaton M, Zhu X, editors. JAD. 2018;62:1091\u2013111.","DOI":"10.3233\/JAD-170850"},{"key":"1595_CR23","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KGM Moons","year":"2015","unstructured":"Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1-73.","journal-title":"Ann Intern Med"},{"key":"1595_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Su\u00e1rez-Calvet M, et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol. 2024;20:426\u201339.","journal-title":"Nat Rev Neurol"},{"key":"1595_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/BF02924688","volume":"31","author":"H Toutenburg","year":"1990","unstructured":"Toutenburg H, Rubin DB. Multiple imputation for nonresponse in surveys. Stat Pap. 1990;31:180\u2013180.","journal-title":"Stat Pap"},{"key":"1595_CR26","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.csda.2005.07.015","volume":"50","author":"W Sauerbrei","year":"2006","unstructured":"Sauerbrei W, Meier-Hirmer C, Benner A, Royston P. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal. 2006;50:3464\u201385.","journal-title":"Comput Stat Data Anal"},{"key":"1595_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-3-030-16399-0_17","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"EW Steyerberg","year":"2019","unstructured":"Steyerberg EW. Validation of Prediction Models. In: Steyerberg EW, editor. Clinical prediction models: a practical approach to development, validation, and updating. Cham: Springer International Publishing; 2019. p. 329\u201344. https:\/\/doi.org\/10.1007\/978-3-030-16399-0_17. Cited 2024 Feb 26."},{"key":"1595_CR28","doi-asserted-by":"publisher","first-page":"e48953","DOI":"10.1371\/journal.pone.0048953","volume":"7","author":"T Samaille","year":"2012","unstructured":"Samaille T, Fillon L, Cuingnet R, Jouvent E, Chabriat H, Dormont D, et al. Contrast-based fully automatic segmentation of white matter hyperintensities: method and validation. Herholz K, editor. PLoS ONE. 2012;7:e48953.","journal-title":"PLoS ONE"},{"key":"1595_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000049147","volume":"13","author":"F Fazekas","year":"2002","unstructured":"Fazekas F, Barkhof F, Wahlund LO, Pantoni L, Erkinjuntti T, Scheltens P, et al. CT and MRI rating of White Matter lesions. Cerebrovasc Dis. 2002;13:31\u20136.","journal-title":"Cerebrovasc Dis"},{"key":"1595_CR30","doi-asserted-by":"publisher","first-page":"e12218","DOI":"10.1111\/jnp.12218","volume":"15","author":"L Alves","year":"2021","unstructured":"Alves L, Cardoso S, Silva D, Mendes T, Mar\u00f4co J, Nogueira J, et al. Neuropsychological profile of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment. J Neuropsychol. 2021;15:e12218.","journal-title":"J Neuropsychol"},{"key":"1595_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/JAD-180048","volume":"66","author":"SE Kim","year":"2018","unstructured":"Kim SE, Woo S, Kim SW, Chin J, Kim HJ, Lee BI, et al. A Nomogram for Predicting amyloid PET positivity in amnestic mild cognitive impairment. J Alzheimer\u2019s Disease. 2018;66:681\u201391.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"1595_CR32","doi-asserted-by":"crossref","unstructured":"Ko H, Ihm JJ, Kim HG, for the Alzheimer\u2019s Disease Neuroimaging Initiative. Cognitive profiling related to cerebral amyloid beta burden using machine learning approaches. Front Aging Neurosci. 2019;11. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2019.00095. Cited 2024 Feb 26.","DOI":"10.3389\/fnagi.2019.00095"},{"key":"1595_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E, et al. Accurate risk estimation of \u03b2-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms. Alzheimer\u2019s Dement. 2019;15:194\u2013204.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1595_CR34","doi-asserted-by":"publisher","first-page":"fcab008","DOI":"10.1093\/braincomms\/fcab008","volume":"3","author":"D Tosun","year":"2021","unstructured":"Tosun D, Veitch D, Aisen P, Jack CR, Jagust WJ, Petersen RC, et al. Detection of \u03b2-amyloid positivity in Alzheimer\u2019s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 2021;3:fcab008.","journal-title":"Brain Commun"},{"key":"1595_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.dadm.2019.09.001","volume":"11","author":"N Maserejian","year":"2019","unstructured":"Maserejian N, Bian S, Wang W, Jaeger J, Syrjanen JA, Aakre J, et al. Practical algorithms for amyloid \u03b2 probability in subjective or mild cognitive impairment. Alz Dem Diag Ass Dis Mo. 2019;11:710\u201320.","journal-title":"Alz Dem Diag Ass Dis Mo"},{"key":"1595_CR36","volume":"15","author":"HS Kwon","year":"2023","unstructured":"Kwon HS, Lee E-H, Kim H-J, Park S-H, Park H-H, Jeong JH, et al. Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers. Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2023;15: e12502.","journal-title":"Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring."},{"key":"1595_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimer\u2019s Dement. 2022;18:283\u201393.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1595_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200230","volume":"14","author":"M Ritchie","year":"2024","unstructured":"Ritchie M, Sajjadi SA, Grill JD. Apolipoprotein E genetic testing in a New Age of Alzheimer Disease Clinical Practice. Neur Clin Pract. 2024;14: e200230.","journal-title":"Neur Clin Pract"},{"key":"1595_CR39","doi-asserted-by":"publisher","first-page":"e200258","DOI":"10.1212\/CPJ.0000000000200258","volume":"14","author":"S Ronay","year":"2024","unstructured":"Ronay S, Tsao JW. The importance of apolipoprotein E genetic testing in the era of amyloid lowering therapies. Neur Clin Pract. 2024;14:e200258.","journal-title":"Neur Clin Pract"},{"key":"1595_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377.","journal-title":"Lancet Neurol"},{"key":"1595_CR41","doi-asserted-by":"crossref","unstructured":"Planche V, Bouteloup V, Pellegrin I, Mangin JF, Dubois B, Ousset PJ, et al. Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology. 2023;100. Available from: https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000201479. Cited 2024 Jun 20.","DOI":"10.1212\/WNL.0000000000201479"},{"key":"1595_CR42","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3233\/JAD-191038","volume":"73","author":"A Ezzati","year":"2020","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, Ezzati A, Harvey DJ, Habeck C, Golzar A, Qureshi IA, et al. Predicting Amyloid-\u03b2 levels in amnestic mild cognitive impairment using machine learning techniques. JAD. 2020;73:1211\u20139.","journal-title":"JAD"},{"key":"1595_CR43","doi-asserted-by":"crossref","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, Kandel BM, Avants BB, Gee JC, Arnold SE, Wolk DA. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-\u03b2 in Mild Cognitive Impairment. Saykin A, editor. JAD. 2015;46:901\u201312.","DOI":"10.3233\/JAD-142943"},{"key":"1595_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neurobiolaging.2024.01.005","volume":"136","author":"I Jang","year":"2024","unstructured":"Jang I, Li B, Rashid B, Jacoby J, Huang SY, Dickerson BC, et al. Brain structural indicators of \u03b2-amyloid neuropathology. Neurobiol Aging. 2024;136:157\u201370.","journal-title":"Neurobiol Aging"},{"key":"1595_CR45","doi-asserted-by":"crossref","unstructured":"Langford O, Raman R, Sperling RA, Cummings J, Sun C-K, Jimenez-Maggiora G, et al. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. J Prev Alzheimers Dis. 2020;7:213\u20138.","DOI":"10.14283\/jpad.2020.44"},{"key":"1595_CR46","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1038\/s41598-021-83911-9","volume":"11","author":"G Shan","year":"2021","unstructured":"Shan G, Bernick C, Caldwell JZK, Ritter A. Machine learning methods to predict amyloid positivity using domain scores from cognitive tests. Sci Rep. 2021;11:4822.","journal-title":"Sci Rep"},{"key":"1595_CR47","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","volume":"20","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, et al. Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2024;20:1214\u201324.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1595_CR48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes-Dumeyer D, Lantigua RA, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimer\u2019s Dement. 2021;17:1353\u201364.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1595_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimer\u2019s Res Therapy. 2022;14:195.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1595_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","volume":"319","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H. Blood-based biomarkers for Alzheimer\u2019s disease\u2014An update. J Neurosci Methods. 2019;319:2\u20136.","journal-title":"J Neurosci Methods"},{"key":"1595_CR51","volume":"16","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Wiste HJ, Bornhorst JA, Bateman RJ, Li Y, Graff-Radford J, et al. Performance of the Lumipulse plasma A\u03b242\/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2024;16: e12545.","journal-title":"Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring."}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01595-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01595-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01595-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T19:04:07Z","timestamp":1728673447000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01595-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01595-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. All participants provided written informed consent. The MEMENTO cohort protocol was approved by the local ethics committee (\u201cComit\u00e9 de Protection des Personnes Sud-Ouest et Outre Mer III\u201d; approval number 2010-A01394-35) and was registered on 16 August 2013 in ClinicalTrials.gov (Identifier: NCT01926249).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the past three years, VP was a local unpaid investigator or sub-investigator for clinical trials granted by NovoNordisk, Biogen, TauRx Pharmaceuticals, Janssen and Alector. He received consultant fees for animal studies from Motac Neuroscience Ltd.All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All other authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}